Alpha-1-antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on federated learning

Table 3 Prevalence of comorbidities in total COPD cohort, and subgroups of non-AATD and AATD COPD patients. The data are given as a percentage. All p-values are calculated with the Chi-squared test for two groups

Comorbidity	COPD total	AATD	Non-AATD	p-value
Acute Ischemic Stroke	1.83	1.82	3.27	0.001
Angina Pectoris	3.82	3.83	2.84	0.143
Arrhythmias	28.31	28.15	46.31	< 0.001
Atrial Fibrillation	21.63	21.47	39.14	< 0.001
Bronchiectasis	99.48	99.49	98.77	0.004
Carotid Stenosis	2.43	2.43	2.14	0.651
Coronary Heart Disease	2.12	2.12	1.89	0.709
Coronary Sclerosis	26.54	26.51	29.20	0.067
Diabetes	26.58	26.52	32.79	< 0.001
Emphysema	98.48	98.51	95.38	< 0.001
Heart Failure	21.23	21.20	25.51	0.001
Hypertension	60.14	60.12	62.51	0.136
Ischemic Heart	30.61	30.59	33.51	0.056
Liver Disease	4.80	4.63	23.49	< 0.001
Myocardial Infarction	8.75	8.72	12.71	< 0.001
Peripheral vascular disorders	15.62	15.55	23.60	< 0.001
Renal Failure	19.22	19.14	28.48	< 0.001
Valvular Disease	9.50	9.42	18.44	< 0.001

ISSN: 1465-993X